Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Earnings for iTeos Therapeutics, Inc. (ITOS)
Earnings in 2023 (TTM): $-109,030,000
According to iTeos Therapeutics, Inc.'s latest financial reports the company's current earnings (TTM) are $-109,030,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of iTeos Therapeutics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-109,030,000 | $-112,642,000 |
| 2022 | $148.74 M | $96.65 M |
| 2021 | $256.46 M | $214.52 M |
| 2020 | $-38,090,000 | $-38,033,000 |
| 2019 | $-22,335,000 | $-22,454,000 |
| 2018 | $-18,046,000 | $-18,057,000 |